View
217
Download
0
Category
Tags:
Preview:
Citation preview
Consortium québécois sur la découverte du médicament
Facilitating creative partnerships in biopharmaceutical research
Ottawa, November 30th , 2009
Diane Gosselin,VP Research and Business Development
Consortium québécois sur la découverte du médicament
The current pharma R&D business model is increasingly unsatisfactory…
… and requires to rethink its operational mode and improve productivity
65.2 billion invested in R&D in 2008 Poor innovative product pipelines Increasing regulatory hurdles Disillusion from expectations of rapid translation from “genes to drugs”
A fostered co-creation of value between academic centers, biotech
companies and the pharmaceutical industry The possibility to finance creative pre-competitive research with
the potential to impact the whole life science sector A more flexible management of IP processes A better way to channel public funds on research agendas
responding to Industry and Regulators needs
Consortium québécois sur la découverte du médicament
Our mission
To identify, finance and support innovative research
activities, primarily focusing on enabling technologies in
drug discovery, fulfilling the innovation needs of the
pharmaceutical industry
To create a collaborative ground between the academic
and private sectors based on trust, creativity and mutual
benefit
Consortium québécois sur la découverte du médicament
Founding Partners
Consortium québécois sur la découverte du médicament
A fully mutualized consortium unlike other existing initiatives
Consortium québécois sur la découverte du médicament
Scope of the funding program
• Promote the development of innovative enabling technologies that can facilitate biopharmaceutical research
• Not intended to fund the development of specific molecules
• Must address the most important challenges of the bio-pharmaceutical industry
• Must generate clear deliverables with immediate applications in the drug discovery or development process
• Promote creativity and collaborations between public and private organizations (strongly encouraged, but not mandatory)
Consortium québécois sur la découverte du médicament
Funding specifics
Amount and Duration $1,000,000 - $3,000,000/project (3 years)
Subject to milestone achievement and satisfactory follow-ups
3-5 projects funded per year
Mentorship
For each project a specific industrial advisory committee ensures that the end-products are well aligned with the needs of the biopharmaceutical research industry
Intellectual property IP belongs to the inventors and their respective institutions
A non exclusive end-user license option will be granted to the CQDM’s industrial sponsors for internal research purposes only
The owners of IP will maintain the right to exploit or to out-license to third parties
Consortium québécois sur la découverte du médicament
2008-2009 competition
12 full applications
78 letters of intent
4 selected projects
3 funded projects
A total of $6.0M in funding Over 70 researchers from 4 universities
and 3 private organizations
Consortium québécois sur la découverte du médicament
1. Identification of biomarkers for measurement of pancreatic beta cell mass, function and stratification of treatment response patients. Principal investigator Eustache Paramithiotis, Caprion Proteomics.Budget : $2.305M
2. Development of new vaccine antigens based on Virus-Like Particles (VLPs). Principal investigator: Louis-Philippe Vézina, Medicago. Budget: $1.775M
3. Multiparametric profiling of G protein-coupled receptor efficacy ligand using multiplexed biosensors: linking signalling signatures to therapeutic efficacy. Principal investigator: Michel Bouvier, Unviersity of Montreal.Budget : $1.827 M
2008-2009 funded projects
Consortium québécois sur la découverte du médicament
1) Innovative technology platforms
2) Translational technologies
3) Cutting edge drug delivery technologies
Research agenda (2009-2010)
This year, priority will be given to the following enabling technologies:
Consortium québécois sur la découverte du médicament
An innovative consortium
Benefits to Pharma companies Access to innovation aligned with the
needs of the industry Excellent leverage (>10 fold) for
R&D investment dollars Closer links with the academic and
the Biotech sectors Cooperative interactions with
competitors Closer interactions with government
bodies
Benefits to Biotech companies and to academic institutions Additional source of funding Access to specialized and dedicated resources Closer links with industrial colleagues Increased international competiveness
Consortium québécois sur la découverte du médicament
Corporate development
CQDM is planning to extend its activities through national and international collaborations
CQDM wishes to enter into bilateral agreements with similar organizations in the US and in Europe to finance joint research projects in drug discovery and development
Aligning international research resources with global pharma R&D agendas is likely to impact the productivity of drug discovery in the industry
Recommended